Premier submitted comments cautioning the DEA to carefully consider how a reduction in manufacturing quotas for certain opioids could rekindle recent drug shortages for injectable opioids and have a negative effect on patients with a legitimate and serious need for these medications. DEA proposes to reduce the aggregate production quotas (APQs) for several schedule II controlled substances in 2020 including:
- Fentanyl – 31% reduction
- Hydromorphone – 25% reduction
- Oxycodone – 9% reduction
These medications are critical to control pain during surgeries, interventional procedures, traumas, burns and other procedures where treatment with alternative pain therapies may not be.
In the comments, Premier urged the DEA to differentiate between solid oral dosage forms and injectables and ensure that quotas for injectable opioids are not impacted by the proposed reduction in APQs. Premier further urged the DEA to develop a process for temporarily reallocating quotas for injectable opioids to able and operational manufacturers to help alleviate ongoing and future potential shortages of injectable opioids.
About Premier, Inc.
Premier Inc. (NASDAQ: PINC) is a leading healthcare improvement company, uniting an alliance of more than 4,000 U.S. hospitals and health systems and approximately 175,000 other providers and organizations to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and consulting and other services, Premier enables better care and outcomes at a lower cost. Premier plays a critical role in the rapidly evolving healthcare industry, collaborating with members to co-develop long-term innovations that reinvent and improve the way care is delivered to patients nationwide. Headquartered in Charlotte, N.C., Premier is passionate about transforming American healthcare. Please visit Premier’s news and investor sites on www.premierinc.com; as well as Twitter, Facebook, LinkedIn, YouTube, Instagram and Premier’s blog for more information about the company.